It was January 2023. Elon Musk owned Twitter, but it wasn’t yet called X. ChatGPT had been released barely six weeks earlier.
Absci CEO Sean McClain — tall, with short, gelled hair and a beard, the kind of all-American entrepreneur who mowed lawns to buy a video game as a kid but instead bought his first truck — got up on health care’s biggest stage, the J.P. Morgan Healthcare Conference. He pitched the synthetic biology company he had founded in a tiny basement lab in 2011, touting what he considered striking new evidence of Absci’s ability to create brand-new antibodies with artificial intelligence.
“Absci is the first and only company to design and validate new antibodies with a zero-shot generative AI,” McClain told a room of investors. “We’re doing this all from scratch on a computer. No one has ever done this before. This completely eliminates all the biological discovery technologies that currently exist, and this truly is the future.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
